Bingham Osborn & Scarborough’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-7,045
| Closed | -$1.5M | – | 12 |
|
|
2021
Q3 | $1.5M | Buy |
7,045
+3,711
| +111% | +$854K | 0.11% | 47 |
|
|
2021
Q2 | $813K | Buy |
3,334
+747
| +29% | +$184K | 0.06% | 58 |
|
|
2021
Q1 | $644K | Buy |
2,587
+134
| +5% | +$32K | 0.05% | 65 |
|
|
2020
Q4 | $564K | Sell |
2,453
-172
| -7% | -$39.7K | 0.04% | 64 |
|
|
2020
Q3 | $667K | Buy |
2,625
+8
| +0.3% | +$1.98K | 0.05% | 83 |
|
|
2020
Q2 | $617K | Buy |
2,617
+177
| +7% | +$40.4K | 0.05% | 85 |
|
|
2020
Q1 | $495K | Buy |
2,440
+28
| +1% | +$6.12K | 0.05% | 88 |
|
|
2019
Q4 | $581K | Sell |
2,412
-461
| -16% | -$102K | 0.05% | 90 |
|
|
2019
Q3 | $556K | Buy |
2,873
+60
| +2% | +$11.5K | 0.05% | 87 |
|
|
2019
Q2 | $518K | Buy |
2,813
+10
| +0.4% | +$1.79K | 0.05% | 88 |
|
|
2019
Q1 | $533K | Sell |
2,803
-309
| -10% | -$59K | 0.05% | 86 |
|
|
2018
Q4 | $606K | Buy |
3,112
+276
| +10% | +$53.8K | 0.06% | 71 |
|
|
2018
Q3 | $588K | Buy |
2,836
+40
| +1% | +$7.88K | 0.05% | 78 |
|
|
2018
Q2 | $516K | Buy |
2,796
+109
| +4% | +$19.3K | 0.05% | 76 |
|
|
2018
Q1 | $458K | Sell |
2,687
-28
| -1% | -$5.14K | 0.04% | 81 |
|
|
2017
Q4 | $472K | Buy |
2,715
+211
| +8% | +$37.3K | 0.04% | 79 |
|
|
2017
Q3 | $467K | Buy |
2,504
+10
| +0.4% | +$1.77K | 0.04% | 77 |
|
|
2017
Q2 | $430K | Sell |
2,494
-3
| -0.1% | -$488 | 0.04% | 75 |
|
|
2017
Q1 | $410K | Buy |
2,497
+3
| +0.1% | +$498 | 0.04% | 77 |
|
|
2016
Q4 | $365K | Buy |
2,494
+89
| +4% | +$13.4K | 0.04% | 81 |
|
|
2016
Q3 | $401K | Sell |
2,405
-300
| -11% | -$50.7K | 0.04% | 80 |
|
|
2016
Q2 | $412K | Buy |
2,705
+52
| +2% | +$8.09K | 0.05% | 78 |
|
|
2016
Q1 | $398K | Buy |
2,653
+300
| +13% | +$44.6K | 0.05% | 81 |
|
|
2015
Q4 | $382K | Hold |
2,353
| – | – | 0.05% | 79 |
|
|
2015
Q3 | $325K | Buy |
2,353
+200
| +9% | +$31.5K | 0.04% | 83 |
|
|
2015
Q2 | $331K | Sell |
2,153
-40
| -2% | -$6.41K | 0.04% | 82 |
|
|
2015
Q1 | $351K | Sell |
2,193
-2,461
| -53% | -$388K | 0.04% | 83 |
|
|
2014
Q4 | $741K | Buy |
4,654
+2,613
| +128% | +$407K | 0.09% | 55 |
|
|
2014
Q3 | $287K | Buy |
2,041
+100
| +5% | +$13.1K | 0.04% | 93 |
|
|
2014
Q2 | $230K | Buy |
+1,941
| New | +$225K | 0.03% | 99 |
|
Other funds holding AMGN
Bingham Osborn & Scarborough's AMGN Position: Q4 2021 in Review
Bingham Osborn & Scarborough sold out of Amgen (AMGN) in Q4 2021, closing a stake of 7,045 shares — an estimated $1.5M sold.
Bingham Osborn & Scarborough first reported a position in AMGN in Q2 2014 and held it in 30 quarters. The position peaked at $1.5M in Q3 2021. 2,293 funds tracked by Wall St. Rank hold AMGN as of Q4 2021.
- Bingham Osborn & Scarborough reported no remaining Amgen position as of Q4 2021 after selling out during the quarter.
- Bingham Osborn & Scarborough sold 7,045 Amgen shares in Q4 2021, an estimated $1.5M.
- Bingham Osborn & Scarborough first reported a position in Amgen in Q2 2014 and held it in 30 quarters.
- Bingham Osborn & Scarborough's Amgen position peaked at $1.5M in Q3 2021.
- 2,293 funds tracked by Wall St. Rank held Amgen as of Q4 2021.
Based on Bingham Osborn & Scarborough's 13F filing for Q4 2021.